Akanda Corp.

AKAN • Drug Manufacturers - Specialty & Generic

$3.35

▼ -0.32 (-8.72%)

Current price

EarningsLatest report: Jun 30, 2025

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$116,224.9

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Positive revenue growth · 93.7%Manageable debt level · 0.08Healthy liquidity · 1.39Weak profitability

Financial data as of: Jun 30, 2025, 12:00 AM UTCLast earnings update: Jul 30, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$3.35

Change-8.72%

Shares Out34.69K

Market Cap$116.22K

Enterprise Value$-2.22M

52W Range2.30 - 209.23

Beta1.73

P/E-0.00

P/S0.07

P/B0.04

P/FCF-0.02

EV/Sales-1.39

Price$3.35

Change-8.72%

Shares Out34.69K

Market Cap$116.22K

Enterprise Value$-2.22M

52W Range2.30 - 209.23

Beta1.73

P/E-0.00

P/S0.07

P/B0.04

P/FCF-0.02

EV/Sales-1.39

EV/EBITDA0.34

EV/FCF0.32

Dividend Yield0.00%

Gross Margin24.91%

Oper. Margin-5.24%

Profit Margin-4.90%

Debt/Eq0.08

Current Ratio1.39

Quick Ratio1.39

Volume30.99K

Avg Volume2.40M

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

69/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

92/100

Why this score▼

Positive revenue growth · 93.7%Manageable debt level · 0.08Healthy liquidity · 1.39Weak profitability

Analyst view

No analyst data available now.

Company Overview

IPO: 3/15/2022

Industry: Drug Manufacturers - Specialty & Generic

P/B i: 0.04

Debt / Equity i: 0.08

Operating Margin: -523.80%

Net Margin: -489.57%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: 0.08

Current Ratio: 1.39

Quick Ratio: 1.39

Status: Good

Insider Transactions

Recent executive and insider activity

HRT FINANCIAL LP

Transaction: 01/16/2026

SELL

Change

-7,868

Price

$1.29

Filing

01/20/2026

Type